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Gram-positive cocci are important causes of both nosocomial and community-acquired infections,
and antimicrobial resistance among these pathogens has become an important problem worldwide.
Since resistance among these organisms can vary substantially by geographic location, we conducted
a multicenter surveillance study with isolates from five Latin American countries (15 medical centers).
Quinupristin/dalfopristin (formerly RP-59500) is a novel streptogramin combination with focused
activity against Gram-positive cocci, many exhibiting emerging resistance. The in vitro activity of
quinupristin/dalfopristin and 12 other antimicrobial agents were evaluated against 1,948 strains
including Staphylococcus aureus (747 strains), coagulase-negative staphylococci (CoNS; 446 strains),
enterococci (429 strains), and various Streptococcus spp. (326 strains). Oxacillin resistance was
observed in 41% of S. aureus (MIC, < 2 µg/ml or > 13 mm) and 40% of CoNS (MIC, < 0.25 µg/ml or
> 18 mm). Vancomycin, teicoplanin, and quinupristin/dalfopristin (MIC90, 0.25 - 1 µg/ml) remained
effective against all strains, but cross-resistance was high among other tested drugs. The quinupristin/
dalfopristin MIC50 for Streptococcus pneumoniae and other streptococci was only 0.5 µg/ml (13% to
28% were penicillin-resistant; 12% to 22% were macrolide-resistant). Enterococci demonstrated
variable inhibition by quinupristin/dalfopristin depending upon identification and the susceptibility
testing method used. The demonstrated quinupristin/dalfopristin activity against Enterococcus faecium
was confirmed, but potential species identification errors with various commercial systems continue
to confuse susceptibility statistics, even though some strains of E. faecium confirmed by PCR-based or
other molecular identification techniques did have quinupristin/dalfopristin MICs of > 4 µg/mL. Most
important, glycopeptide-resistant enterococci are rapidly emerging in Latin America, and quinupristin/
dalfopristin appears active against many of these isolates as well as having potency against nearly all
staphylococci and streptococci tested at < 2 µg/ml or having a zone diameter of > 16 mm. Comparisons
to GSMART results from other continents show nearly identical quinupristin/dalfopristin activity for
each Gram-positive species tested. These results define the role of quinupristin/dalfopristin in Latin
American medical centers and provide a benchmark for future in vitro comparisons.
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Several studies have shown a progressive increase
in antimicrobial resistance among Gram-positive cocci,
especially in the United States (U.S.). Vancomycin-
resistant enterococci (VRE) appeared and
disseminated all over the U.S. in the early 1990s. Pfaller
and colleagues [1] in the SENTRY Antimicrobial
Surveillance Program listed a vancomycin resistance
rate in bloodstream enterococci at 16% to 18% in
1997, having increased from less than 1% in 1989.
However, in spite of the continuing increase in the
22 BJID 2001; 5 (February)
www.infecto.org.br/bjid.htm
vancomycin resistance rates among enterococci in the
U.S., this pathogen has rarely been described in Latin
American countries [1-3].
Oxacillin resistance among staphylococci has been
a chronic problem in most U.S. and Latin American
tertiary care hospitals. Data from the SENTRY Program
has shown that 30% to 50% of Staphylococcus aureus
strains collected in Latin American hospitals were
resistant to oxacillin and most of the anti-staphylococci
drugs available, except the glycopeptides [3, 4].
Fortunately, S. aureus strains with reduced
susceptibility to glycopeptides have not been reported
in Latin America yet [5]. However, glycopeptide
(teicoplanin) resistance has been reported among
coagulase-negative staphylococci (CoNS) in Brazil,
especially among S. haemolyticus. Using the
published susceptible breakpoint for oxacillin (≥ 0.25
µg/mL), resistance to this antimicrobial agent can
reach 75% among CoNS strains in Latin American
medical centers [6].
In the search for therapeutic agents to treat serious
Gram-positive infections, the streptogramin combination
of quinupristin/dalfopristin (Synercid®) has been widely
studied [7]. In this work, we evaluated the in vitro
activity of quinupristin/dalfopristin against Gram-positive
cocci collected in 15 Latin American medical centers,
as part of the international surveillance program called
Global Synercid® Microbiologic Assessment of
Resistance Trends (GSMART).
Materials and Methods
Study Design. Fifteen medical centers were recruited
in South America to participate in a study known as
GSMART. Six of these centers were located in Brazil,
5 in Argentina, 2 in Chile, 1 in Ecuador, and 1 in
Venezuela. In Brazil, the medical centers were
distributed among 4 cities including São Paulo (3
centers), Rio de Janeiro (1 center), Florianópolis (1
center) and Porto Alegre (1 center). The Argentinean
centers were located in Buenos Aires, San Isidro,
Cordoba, Rosário and Tandil. Both Chilean centers
were in Santiago, and the centers in Ecuador and
Venezuela were located in Quito and Caracas,
respectively. The participants performed all in vitro
susceptibility tests on-site for approximately 150 strains
of Gram-positive organisms using reagents provided.
Organisms. Each participating site was asked to process
the following Gram-positive bacterial species (150 total
strains): 1) oxacillin-susceptible S. aureus (30 strains)
and oxacillin-resistant S. aureus (20 strains); 2)
oxacillin-susceptible CoNs (15 strains) and oxacillin-
resistant CoNs (20 strains); 3) Enterococcus faecalis
(10 strains) and Enterococcus faecium (30 strains),
or 40 strains of enterococci that were not identified to
the species level; and 4) 20 strains of Streptococcus
pneumoniae and 5 strains of other streptococci which
could include viridans gr. and β-haemolytic
streptococci. Various demographic information was
collected including body site of infection, hospital unit/
service, and date of culture. All strains were collected
from patient infections in 1998, and the first trimester
of 1999. Clinical specimens included blood, cerebral
spinal fluid, skin and skin structure, bone, intra-
abdominal infections, and lower and upper respiratory
tract samples.
Susceptibility testing methods. Isolates of
Streptococcus spp. were tested by using Etest (AB
BIODISK, Solna, Sweden). All other organisms were
tested by using either broth microdilution (Brazilian
centers) or disk diffusion (all other participants). Broth
microdilution trays were manufactured by Dade/
Microscan (Sacramento, CA, US). Susceptibility tests
were performed following the procedures described
by the National Committee for Clinical Laboratory
Standards (NCCLS) [8].
Antimicrobial Agents: S. pneumoniae, β-haemolytic
and viridans gr. streptococci were tested against
penicillin, cefotaxime, erythromycin, vancomycin,
teicoplanin, and quinupristin/dalfopristin. S. aureus and
CoNS were tested against erythromycin, clindamycin,
cefazolin, cefotaxime, vancomycin, teicoplanin,
ciprofloxacin, chloramphenicol, doxycycline and
quinupristin/dalfopristin. Ampicillin and gentamicin were
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added for those participants that used commercial broth
microdilution trays. Enterococci were tested against
ampicillin, vancomycin, teicoplanin, ciprofloxacin,
chloramphenicol, doxycycline, and quinupristin/
dalfopristin.
Subcultures of organisms exhibiting a MIC of >1
µg/mL or an inhibition zone diameter of < 19 mm for
quinupristin/dalfopristin were forwarded to the
microbiology monitoring sites at the Federal University
of São Paulo (São Paulo, Brazil) and the University of
Iowa (Iowa City, IA, US) for further characterization.
Identification to species level and susceptibility testing
were repeated, and the database was corrected when
necessary. The susceptibility testing results were
recorded as a MIC (µg/mL) or zone diameter (mm)
and then interpreted by NCCLS [8, 9] susceptible
criteria as follows: for S. pneumoniae, quinupristin/
dalfopristin at ≤ 1 µg/mL or ≥ 19 mm, erythromycin at
≤ 0.25 µg/mL or ≥ 23 mm, vancomycin at ≤ 4 µg/mL
or ≥ 15 mm (staphylococci) or > 17mm (enterococci),
teicoplanin at ≤ 8 µg/mL or ≥ 14 mm, ciprofloxacin at
≤ 1 µg/mL or ≥ 21 mm, oxacillin at < 2 µg/mL or ≥ 13
mm (including CoNS) [10], clindamycin at ≤ 0.5 µg/
mL or ≥ 21 mm, doxycycline at ≤ 4 µg/mL or ≥ 16
mm, ampicillin at ≤ 8 µg/mL or ≥ 17 mm,
chloramphenicol at ≤8 µg/mL or ≥ 18 mm, and all
tested cephalosporins (staphylococci only) at ≤ 8 µg/
mL or ≥ 18 mm for cefazolin and cefuroxime, or at ≥
23 mm for cefotaxime.
Only data sets with acceptable quality control results
were analyzed [8]. Quality control monitoring was
performed at the Federal University of São Paulo and
at the University of Iowa. The quality control organisms
were: S. aureus ATCC 25923 (disk diffusion) or
ATCC 29213 (Etest and broth microdilution), and E.
faecalis ATCC 29212.
Pulsed-field gel electrophoresis (PFGE). PFGE of
chromosomal DNA was performed on E. faecium
strains resistant to vancomycin and/or quinupristin/
dalfopristin, as described by Pfaller, et al. [11].
Restriction digestion of chromosomal DNA was
performed with SmaI and the resultant restriction
fragments were resolved in a 1% agarose gel with a
CHEF-DR II system (Bio-Rad Laboratories,
Richmond, CA, US). The pulsed time ranged from 5 s
to 30 s over 23 hs at 13° C and 6 V/cm. PFGE patterns
were considered identical if they shared every band,
similar if they differed from one another by only 1 to 3
bands, and different if they differed by 4 or more bands.
Results
Table 1 presents the Etest results (MICs) for
quinupristin/dalfopristin and 5 other antimicrobial agents
tested against 244 pneumococci and 82 other
streptococcal strains. The quinupristin/dalfopristin
MIC90 was 1 µg/mL for both groups, and all
streptococcal strains tested were considered susceptible
(MIC, ≤ 1 µg/mL). Twenty-eight percent of the S.
pneumoniae strains were non-susceptible to penicillin
(MIC, > 0.06 µg/ml), while 12 strains (5%) harbored
high-level resistance (MIC, > 2 µg/mL). Resistance to
cefotaxime was detected in 10% of the S. pneumoniae
(MIC90, 0.5 µg/mL) strains and 7% of the other
streptococcal species strains, while resistance to
erythromycin was much higher (12% among
pneumoccci and 22% among other streptococcal
species). All streptococcal isolates were susceptible
to vancomycin (MIC90, 0.5 µg/mL to 0.75 µg/mL).
The results of testing 747 S. aureus strains are
summarized in Table 2. Two test methods were used
and the results are indexed by the oxacillin susceptibility
category. Isolates from the Brazilian centers were tested
by broth microdilution while isolates from other
countries were evaluated by the disk diffusion method.
The oxacillin-susceptible S. aureus (OSSA) strains
were susceptible to most antimicrobial agents evaluated,
although some degree of resistance was detected for
erythromycin (12% to 14% resistance). In contrast,
oxacillin-resistant S. aureus (ORSA) showed high rates
of resistance to most antimicrobial agents evaluated.
Only quinupristin/dalfopristin (MIC90, 0.5 µg/mL,
100% susceptibility), vancomycin (MIC90, 1 µg/mL,
100% susceptibility), and teicoplanin (MIC90, 0.5 µg/
mL, 97% to 100% susceptibility) showed reasonable
activity against this pathogen (Table 2).
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Table 1. Antimicrobial activity of quinupristin-dalfopristin and 5 other compounds tested against 326 streptococci
strains isolated in Latin America
Figure 1.
λ 1 2 3 4 5 6 7
Organisms (no. tested) Antimicrobial MIC (µg/mL) % susceptible
Agents 50% 90% (breakpoint)
S. pneumoniae
(244) Quinupristin/Dalfopristin 0.5 1.0 100 (< 1.0 µg/mL)
Penicillin 0.016 0.75 72 (< 0.06 µg/mL)
Cefotaxime 0.032 0.5 90 (< 0.5 µg/mL)
Erythromycin 0.064 0.75 88 (< 0.25 µg/mL)
Vancomycin 0.25 0.5 100 (< 1 µg/mL)
Teicoplanin 0.032 0.125 - a
Other streptococci
(82) Quinupristin/Dalfopristin 0.5 1.0 100 (< 1.0 µg/mL)
Penicillin 0.016 0.38 87 (< 0.12 µg/mL)
Cefotaxime 0.047 0.5 93 (< 0.5 µg/mL)
Erythromycin 0.094 2.0 78 (< 0.25 µg/mL)
Vancomycin 0.25 0.75 100 (< 1 µg/mL)
Teicoplanin 0.06 0.25 - a
a. All pneumococci inhibited at < 0.5 µg/mL and all streptococci inhibited at < 2.0 µg/mL.
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Table 2. Antimicrobial activity of quinupristin-dalfopristin and 11 other compounds tested against 747 S. aureus
strains isolated in Latin America
Organisms Antimicrobial MIC (mg/mL) % susceptible/resistant (n) by:
(no. tested) Agents 50% 90% Broth microdilution Disk diffusion
S. aureus
Oxacillin-susceptible (n=178) (n=260)
(438) Quinupristin/ 0.25 0.25 100 / 0 100 / 0
Dalfopristina
Erythromycin 0.12 >16 84 / 12 76 / 14
Clindamycin 0.12 0.25 97 / 2 92 / 4
Ampicillin 4 >16 69 / 30 NT
Cefazolin 0.25 0.5 100 / 0 100 / 0
Cefotaxime 0.5 1 100 / 0 100 / 0
Vancomycin 0.5 1 100 / 0 100 / 0
Teicoplanin 0.25 0.5 100 / 0 100 / 0
Ciprofloxacin 0.12 1 97 / 0 92 / 2
Gentamicin 0.25 2 93 / 0 NT
Chloramphenicol 4 8 91 / 4 94 / 4
Doxycycline 2 4 96 / 0 97 / 2
Oxacillin-resistant (n=144) (n=165)
(309) Quinupristin/ 0.25 0.5 100 / 0 100 / 0
Dalfopristina
Erythromycin >16 >16 0 / 100 8 / 91
Clindamycin >16 >16 5 / 95 1 / 89
Ampicillin >16 >16 0 / 100 0 / 100
Cefazolin >16 >16 0 / 100 0 / 100
Cefotaxime >32 >32 0 / 100 0 / 100
Vancomycinb 0.5 1 100 / 0 100 / 0
Teicoplanin 0.5 0.5 100 / 0 97 / 0
Ciprofloxacin 2 2 4 / 82 13 / 84
Gentamicin >8 >8 4 / 82 NT
Chloramphenicol >16 >16 22 / 72 54 / 44
Doxycycline 8 >8 40 / 10 51 / 26
a
 Quinupristin/Dalfopristin susceptibility defined as MIC, < 1 mg/mL or > 19 mm [8, 9].
b
 Only 1 strain with a MIC of 4.0 mg/mL.
NT: Not tested.
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Table 3. Antimicrobial activity of quinupristin-dalfopristin and 11 other compounds tested against 446 coagulase-
negative staphylococci (CoNS) strains isolated in Latin America
Organisms Antimicrobial MIC (mg/mL) % susceptible/resistant (n) by:
(no. tested) Agents 50% 90% Broth Microdilution Disk Diffusion
CoNS
Oxacillin-susceptible (n=52) (n=119)
(171)a Quinupristin/ 0.12 0.25 100 / 0 100 / 0
Dalfopristinb
Erythromycin 0.12 16 69 / 25 62 / 31
Clindamycin 0.12 0.5 92 / 4 91 / 5
Ampicillin 1 16 89 / 10 NT
Cefazolin 0.25 0.5 100 / 0 100 / 0
Cefotaxime 0.5 1 100 / 0 100 / 0
Vancomycin 0.5 1 100 / 0 100 / 0
Teicoplanin 0.5 1 100 / 0 100 / 0
Ciprofloxacin 0.12 0.5 92 / 0 91 / 6
Gentamicin 0.12 0.5 94 / 4 NT
Chloramphenicol 4 8 92 / 6 94 / 5
Doxycycline 2 8 89 / 2 88 / 9
Oxacillin-resistant (n=102) (n=173)
(275) Quinupristin/ 0.25 1 99 / 0 c 100 / 0
Dalfopristinb
Erythromycin >16 >16 27 / 72 29 / 68
Clindamycin >16 >16 32 / 66 42 / 52
Ampicillin >16 >16 0 /100 NT
Cefazolin >16 >16 0 /100 0 /100
Cefotaxime >32 >32 0 /100 0 /100
Vancomycind 1 2 100 / 0 100 / 0
Teicoplanine 1 2 100 / 0 99 / 0
Ciprofloxacin 2 2 28 / 58 49 / 45
Gentamicin 8 >8 24 / 51 NT
Chloramphenicol 16 >16 37 / 51 54 / 42
Doxycycline 2 4 89 / 2 66 / 27
a
 Oxacillin susceptibility was defined as MIC < 0.25 µg/mL or > 18 mm [8,9].
b
 Quinupristin/dalfopristin susceptibility was defined as MIC <1 µg/mL or >19 mm [8, 9].
c
 One strain with a MIC of 2 µg/mL.
d
 One strain with a MIC of 4 µg/mL.
e
 One strain with a MIC of 8 µg/mL
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Table 4. Antimicrobial activity of quinupristin-dalfopristin and 6 other compounds tested against 429 enterococci
strains isolated in Latin America
Organisms Antimicrobial MIC (µg/mL) % susceptible/resistant (n) bya
(no. tested) Agents 50% 90% Broth Microdilution Disk Diffusion
E. faecium
Vancomycin- (n=49) (n=45)
susceptible (94) Quinupristin/ 0.5 2 80 / 2 96 / 2
Dalfopristin
Ampicillin 0.5 16 84 / 16 72 / 28
Vancomycin 0.5 2 100 / 0 100 / 0
Teicoplanin 0.25 0.5 100 / 0 100 / 0
Ciprofloxacin 2 >2 33 / 53 24 / 24
Chloramphenicol 4 16 88 / 8 87 / 0
Doxycycline 2 >8 78 / 16 61 / 22
Vancomycin- (n=17) (n=4)
resistant (21) Quinupristin/ 8 8 12 / 88 100 / 0
Dalfopristin
Ampicillin >16 >16 0 / 100 0 / 100
Vancomycin >16 >16 0 / 100 0 / 100
Teicoplanin >16 >16 0 / 100 0 / 100
Ciprofloxacin >2 >2 0 / 94 0 / 50
Chloramphenicol 8 8 94 / 6 75 / 25
Doxycycline 2 8 82 / 0 75 / 25
E. faecalis (n=83) (n=140)
(223) Quinupristin/ 8 >16 1 / 90 13 / 71
Dalfopristin
Ampicillin 1 2 99 / 1 93 / 7
Vancomycin 1 2 98 / 2 96 / 1
Teicoplanin 0.12 0.12 98 / 2 100 / 0
Ciprofloxacin 2 >2 44 / 32 14 / 28
Chloramphenicol 8 >16 59 / 35 69 / 14
Doxycycline 4 >8 60 / 23 44 / 39
Enterococcus (n=44) (n=47)
spp. (91) Quinupristin/ 0.12 2 73 / 2 94 / 4
Dalfopristin
Ampicillin 0.50 2 91 / 9 89 / 11
Vancomycin 0.25 4 91 / 9 87 / 0
Teicoplanin 0.12 0.25 91 / 9 94 / 2
Ciprofloxacin 1 >2 72 / 14 11 / 43
Chloramphenicol 4 8 91 / 9 36 / 30
Doxycycline 2 2 98 / 2 23 / 60
a
 Quinupristin/dalfopristin susceptibility was defined as MIC, < 1 µg/mL or > 19 mm [8, 9].
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Table 3 shows the results for the CoNS species
(446 strains). Like the results for S. aureus listed above,
quinupristin/dalfopristin, vancomycin, and teicoplanin
were the most active compounds with quinupristin/
dalfopristin usually being 2- to 4-fold more potent.
Similar to ORSA strains, oxacillin-resistant CoNS
showed high rates of resistance to all other tested
antimicrobial agents and only doxycycline inhibited more
than one-half of those strains. On the other hand,
oxacillin-susceptible CoNS showed high rates of
susceptibility with more than 90% of strains being
inhibited by most antimicrobial agents, except
erythromycin (62% to 69% susceptibility) and
doxycycline (88% to 89% susceptibility). Ciprofloxacin
inhibited 91% to 92% of the oxacillin-susceptible CoNS
strains at the susceptible breakpoint (< 1 µg/mL), but
only 28% to 49% of the oxacillin-resistant strains were
ciprofloxacin-susceptible. One oxacillin-resistant
CoNS isolate with intermediate resistance to
quinupristin/dalfopristin (MIC, 2 µg/mL), and 1 isolate
with intermediate resistance to teicoplanin (MIC, 8 µg/
mL) were detected.
In Table 4, only the most active drugs tested against
the enterococci (429 strains) are listed. Among those
isolates, 338 (78.8%) were identified to the species
level by the participating laboratories, dominated by
E. faecalis and E. faecium. E. faecium isolates were
divided according to their susceptibility to vancomycin.
Among the 115 E. faecium isolates evaluated, 21
(18.2%) were found to be vancomycin-resistant.
Quinupristin/dalfopristin showed good activity against
vancomycin-susceptible E. faecium (MIC90, 2 µg/mL)
with only 2 isolates (2%) showing resistance. However,
18% of the vancomycin-susceptible isolates evaluated
by broth microdilution (Brazil), and 2% of the isolates
tested by the disk diffusion method demonstrated
intermediate resistance (MIC, 2 µg/mL or zone
diameter of 16 mm to18 mm) to quinupristin/
dalfopristin.
Of the 21 vancomycin-resistant E. faecium isolates,
17 were from Brazil and 4 from Argentina. All the
Brazilian vancomycin-resistant strains were isolated in
São Paulo (3 hospitals), and 15 of those strains (88%)
were also resistant to quinupristin/dalfopristin. Those
15 E. faecium strains that showed resistance to both
vancomycin and quinupristin/dalfopristin, and 2
vancomycin-resistant quinupristin/dalfopristin-
susceptible E. faecium strains from Argentina were
typed by PFGE. Thirteen of the 15 Brazilian isolates
(87%) presented a unique major PGFE pattern (called
A), indicating clonal dissemination (Figure 1). The
Argentinean strains showed PFGE patterns different
from each other and from the epidemic Brazilian clone.
Ampicillin was active against 72% to 84% of the
vancomycin-susceptible E. faecium, but none of the
vancomycin-resistant strains were ampicillin-
susceptible. On the other hand, chloramphenicol and
doxycycline showed moderate in vitro activity against
both vancomycin-susceptible and -resistant E.
faecium. Ampicillin, vancomycin, and teicoplanin were
very active against E. faecalis and Enterococcus spp.
(Table 4). As expected, quinupristin/dalfopristin showed
limited activity against E. faecalis and variable activity
against Enterococcus spp., since these strains were
not identified to the species level and could contain
some isolates of E. faecium.
Discussion
Antimicrobial resistance has developed very rapidly
in recent years, especially among Gram-positive cocci
[12-14]. This has created an acute need for effective
agents. Quinupristin/dalfopristin (formerly RP 59500)
seems to be a potential alternative therapeutic
antimicrobial for use in institutions facing the problem
of multiresistant Gram-positive cocci. This compound
is a water-soluble synthetic streptogramin combination
of quinupristin (a streptogramin B) and dalfopristin (a
streptogramin A) at a ratio of 30:70 [7]. Its described
activity is focused against Gram-positive species and a
few Gram-negative organisms. The action of
streptogramins is generally bactericidal, in contrast to
either component alone or structurally similar macrolide
antimicrobials. Quinupristin/dalfopristin activity is 10-
fold to 100-fold greater than its component potencies
and extends to organisms with documented MLSB
resistance patterns [15, 16]. Resistance to
Antimicrobial Susceptibility of Quinupristin/Dalfopristin
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streptogramin combinations can occur by one of several
resistance mechanisms including modified target, active
efflux, or block of permeases, but these are generally
uncommon [15-17].
In this multicenter, international investigation,
quinupristin/dalfopristin demonstrated a broad
antimicrobial spectrum and potency against S.
pneumoniae (100% susceptibility), Streptococcus spp.
(100% susceptibility), S. aureus (100% susceptibility),
CoNS (100% susceptibility), and vancomycin-
susceptible E. faecium (80% to 96% susceptibility).
The streptogramin activity was evaluated in a
background of increasing clinical resistance. The
resistance of S. pneumoniae to penicillin and macrolide
is already very high in some Latin American countries,
and seems to be continuously increasing [18, 19].
Staphylococci resistant to oxacillin and many other
antimicrobial agents are also very frequent in Latin
American countries [20, 21]. In addition, we have
recently been confronted with the problem of
vancomycin-resistant enterococci (VRE) [22].
The compromised activity of quinupristin/dalfopristin
against some strains of vancomycin-resistant E.
faecium detected in this study was unexpected because
in a large, multicenter study performed in 1996 to1997
in the U.S. (including 326 vancomycin-resistant E.
faecium strains), the MIC50 and MIC90 was 0.5 µg/
mL and 1 µg/mL, respectively [7]). This unusual
resistance pattern was mainly due to the intra- and inter-
hospital dissemination of a single resistant clone. The
results of molecular typing were very important to
understand the rapid emergence of VRE in Brazil. Until
recently, this pathogen was rarely isolated in Brazilian
hospitals [22]. This epidemic increase of VRE
prevalence is mainly due to the dissemination of various
resistant clones. Unfortunately, the predominant
Brazilian VRE clone has also acquired low-level
resistance to quinupristin/dalfopristin.
The bacteriostatic effects of quinupristin/dalfopristin
on E. faecium, especially those isolates with resistance
to vancomycin and macrolides, must be emphasized
[23]. Streptogramins would be expected to kill only
those enterococcal isolates with erythromycin
susceptible test results [23]. Substantial clinical (73.6%)
and microbiological (70.5%) success rates have been
obtained by treatment with quinupristin/dalfopristin for
vancomycin-resistant E. faecium infections in patients
with a severe underlying condition such as diabetes
mellitus, organ transplantation, mechanical ventilation,
dialysis, chronic liver disease with cirrhosis, or
oncological disorder, for which no other therapeutic
alternative has been available [24]. However, physicians
who wish to use quinupristin/dalfopristin for a
bactericidal action, especially in clinical settings such
as endocarditis, should seek additional erythromycin
test results to guide therapy within appropriate
indications [25]. Such attention to detail in the
microbiology diagnosis and susceptibility tests should
limit the occurrence of resistance emerging to
quinupristin/dalfopristin chemotherapy [26].
The microbiology laboratory diagnosis will have a
unique, but correctable, problem with the quinupristin/
dalfopristin susceptibility tests. The selective potency
of quinupristin/dalfopristin against E. faecium among
all other Enterococcus species has uncovered the
potential for false resistance due to misidentification of
enterococcal organisms by several commercial systems
[27, 28]. A correct species identification is essential
for the appropriate clinical use of this new compound.
Supplemental rapid tests (motility, pigment production,
xylose and/or arabinose fermentation) and the
examination of antimicrobial susceptibility patterns
(ampicillin resistance usually indicates E. faecium;
ampicillin-susceptibility favors an E. faecalis
identification) could minimize the reporting of inaccurate
results [29].
In conclusion, after testing nearly 2,000 clinical
bacterial isolates from 15 Latin American medical
centers, the results presented here indicate the favorable
spectrum of quinupristin/dalfopristin compared to other
contemporary antimicrobial agents. This streptogramin
(quinupristin/dalfopristin), along with other
investigational agents [12, 14, 30-32], is urgently
needed for therapy of serious Gram-positive infections
and offers an alternative to glycopeptide therapy. The
role of quinupristin/dalfopristin in infectious disease
practice still awaits more extensive clinical data and
experience. This agent should be selected based on
Antimicrobial Susceptibility of Quinupristin/Dalfopristin
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the treatment benefit for the patients at risk versus
the potential for adverse drugs events. Our results
also demonstrate the importance of antimicrobial
resistance surveillance programs in guiding empirical
regimens, and for focusing intervention controls of
antimicrobial resistance in distinct geographic areas
(example: São Paulo), hospitals, and possibly within
services/wards.
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